We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
J. Clin. Oncol 2022 Nov 17;[EPub Ahead of Print], P Hillmen, B Eichhorst, JR Brown, N Lamanna, SM O'Brien, CS Tam, L Qiu, M Kazmierczak, K Zhou, M Šimkovič, J Mayer, A Gillespie-Twardy, M Shadman, A Ferrajoli, PS Ganly, R Weinkove, S Grosicki, A Mital, T Robak, A Österborg, HA Yimer, T Salmi, M Ji, J Yecies, A Idoine, K Wu, J Huang, W Jurczak